These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22699315)

  • 1. [Recombinant factor VIIa for the treatment of exsanguinating trauma patients: a matched-pair analysis from the Trauma Registry of the German Society for Trauma Surgery].
    Wafaisade A; Lefering R; Maegele M; Helm P; Braun M; Paffrath T; Bouillon B;
    Unfallchirurg; 2013 Jun; 116(6):524-30. PubMed ID: 22699315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of recombinant factor VIIa in US military casualties for a five-year period.
    Wade CE; Eastridge BJ; Jones JA; West SA; Spinella PC; Perkins JG; Dubick MA; Blackbourne LH; Holcomb JB
    J Trauma; 2010 Aug; 69(2):353-9. PubMed ID: 20699744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
    Perkins JG; Schreiber MA; Wade CE; Holcomb JB
    J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
    Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
    J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation management of bleeding trauma patients is changing in German trauma centers: an analysis from the trauma registry of the German Society for Trauma Surgery.
    Wafaisade A; Lefering R; Maegele M; Lendemans S; Flohé S; Hussmann B; Defosse JM; Probst C; Paffrath T; Bouillon B;
    J Trauma Acute Care Surg; 2012 Apr; 72(4):936-42. PubMed ID: 22491608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association.
    Knudson MM; Cohen MJ; Reidy R; Jaeger S; Bacchetti P; Jin C; Wade CE; Holcomb JB
    J Am Coll Surg; 2011 Jan; 212(1):87-95. PubMed ID: 21115374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients.
    Nascimento B; Lin Y; Callum J; Reis M; Pinto R; Rizoli S
    Clinics (Sao Paulo); 2011; 66(1):101-6. PubMed ID: 21437444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.
    Morse BC; Dente CJ; Hodgman EI; Shaz BH; Nicholas JM; Wyrzykowski AD; Salomone JP; Vercruysse GA; Rozycki GS; Feliciano DV
    Am Surg; 2011 Aug; 77(8):1043-9. PubMed ID: 21944521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge.
    Wafaisade A; Lefering R; Maegele M; Brockamp T; Mutschler M; Lendemans S; Banerjee M; Bouillon B; Probst C;
    J Trauma Acute Care Surg; 2013 Feb; 74(2):387-3; discussion 393-5. PubMed ID: 23354229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
    Stein DM; Dutton RP; Kramer ME; Scalea TM
    J Trauma; 2009 Jan; 66(1):63-72; discussion 73-5. PubMed ID: 19131807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant factor VIIA for control of combat-related haemorrhage.
    Woodruff SI; Dougherty AL; Dye JL; Mohrle CR; Galarneau MR
    Emerg Med J; 2010 Feb; 27(2):121-4. PubMed ID: 20156864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated coagulation factor VII and bleeding trauma patients.
    Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
    J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.
    Rizoli SB; Boffard KD; Riou B; Warren B; Iau P; Kluger Y; Rossaint R; Tillinger M;
    Crit Care; 2006; 10(6):R178. PubMed ID: 17184516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage.
    Harrison TD; Laskosky J; Jazaeri O; Pasquale MD; Cipolle M
    J Trauma; 2005 Jul; 59(1):150-4. PubMed ID: 16096555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients.
    Dutton RP; Hess JR; Scalea TM
    J Clin Anesth; 2003 May; 15(3):184-8. PubMed ID: 12770653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of recombinant factor VIIa to facilitate organ donation in trauma patients with devastating neurologic injury.
    Stein DM; Dutton RP; Alexander C; Miller J; Scalea TM
    J Am Coll Surg; 2009 Jan; 208(1):120-5. PubMed ID: 19228513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients.
    Felfernig M;
    J R Army Med Corps; 2007 Mar; 153(1):32-9. PubMed ID: 17575875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding.
    Payen JF; Berthet M; Genty C; Declety P; Garrigue-Huet D; Morel N; Bouzat P; Riou B; Bosson JL;
    Br J Anaesth; 2016 Oct; 117(4):470-476. PubMed ID: 28077534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa in trauma patients with the 'triad of death'.
    Mitra B; Cameron PA; Parr MJ; Phillips L
    Injury; 2012 Sep; 43(9):1409-14. PubMed ID: 21345431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: a systematic review.
    Devlin R; Bonanno L; Badeaux J
    JBI Database System Rev Implement Rep; 2016 Mar; 14(3):116-38. PubMed ID: 27532142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.